Form 4: Phreesia SVP, Life Sciences, David Linetsky, Reports Acquisition of Common Stock and Restricted Stock Units

David Linetsky, SVP of Life Sciences at Phreesia, Inc., reports acquiring common stock and restricted stock units (RSUs) in lieu of cash bonuses.

Summary

• David Linetsky, SVP of Life Sciences at Phreesia, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On September 6, 2024, Linetsky acquired 2,816 shares of common stock and 234 RSUs indirectly through his spouse.
• The 2,816 shares were acquired as fully vested RSUs in lieu of 50% of his cash bonus for the first half of the fiscal year ending January 31, 2025, under Phreesia's Senior Executive Cash Incentive Bonus Plan.
• Linetsky elected to convert the bonus portion into RSUs representing 115% of the earned cash bonus amount, with the number of RSUs based on a per share value of $23.55, the closing price of Phreesia's common stock on September 6, 2024.
• The 234 RSUs were acquired as fully vested RSUs in lieu of 50% of his spouse's cash bonus for the first half of the fiscal year ending January 31, 2025, under Phreesia's Variable Compensation Plan.
• His spouse elected to convert the bonus portion into RSUs representing 115% of the earned cash bonus amount, with the number of RSUs based on a per share value of $23.55, the closing price of Phreesia's common stock on September 6, 2024.
• Following the reported transactions, Linetsky directly owns 205,034 shares of common stock and indirectly owns 9,187 shares through his spouse.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing executive compensation. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The acquisition of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future prospects.
• The election to receive RSUs in lieu of cash bonuses demonstrates a commitment to the company's long-term success.

Future Outlook

There are no explicit forward-looking statements in this document.

Industry Context

Executive compensation practices, including the use of stock-based compensation, are common in the technology and healthcare industries to align management's interests with those of shareholders. This filing reflects a standard practice of granting RSUs in lieu of cash bonuses.

Comparison to Industry Standards

• Stock-based compensation is a common practice among publicly traded companies, particularly in the tech and healthcare sectors, to incentivize executives and align their interests with shareholders.
• Companies like Veeva Systems and Cerner (now Oracle Health) also utilize stock options and RSUs as part of their executive compensation packages.
• The percentage of bonus converted to RSUs (115% in this case) and the vesting schedules can vary widely based on company performance and industry benchmarks.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns executive compensation with company performance.
• Employees may view the option to receive RSUs in lieu of cash bonuses as a positive benefit.

Key Dates